This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Teriparatide
Recombinant PTH 1-34 — first true bone-ANABOLIC drug, given as daily SC injection up to 2 years for severe osteoporosis.
Aliases (4)
Overview
What is Teriparatide?
Teriparatide is a recombinant fragment (1-34 amino acids) of human parathyroid hormone (PTH), FDA-approved as Forteo for osteoporosis. It is one of the only anabolic (bone-building) osteoporosis treatments, distinct from antiresorptives like bisphosphonates.
Key Benefits
Increases bone mineral density and reduces fracture risk in osteoporosis, promotes new bone formation rather than only slowing breakdown, and may aid fracture healing and select dental indications.
Mechanism of Action
Intermittent (once-daily) administration of PTH(1-34) preferentially activates osteoblasts (bone-building cells) over osteoclasts via PTH1 receptor signaling, increasing bone formation. Continuous PTH exposure causes the opposite (bone resorption), so the pulsed daily injection regimen is critical.
Molecular Information
Length
34 amino acids
Pharmacokinetics
▸ Reconstitution Lyophilized peptide
Reconstitute lyophilized peptide with bacteriostatic water (BAC) using sterile technique. Calculator below converts vial mg + diluent mL into syringe units.
- 1 Wipe BAC water vial + peptide vial stoppers with isopropyl alcohol.
- 2 Draw the planned diluent volume into a 1 mL syringe.
- 3 Inject diluent slowly down the inside wall of the peptide vial — do NOT spray onto powder.
- 4 Swirl gently (do not shake) until fully dissolved. Solution should be clear.
- 5 Label vial with date reconstituted; refrigerate 2-8 °C.
- 6 Use within 30 days for most peptides (BPC-157 / TB-500 ~ 60 days at 4 °C).
Peptide Interactions
(concurrent) — DATA trial showed additive BMD effect; emerging combination strategy in highest-risk patients
(sequential, post-teriparatide) — locks in gains, considered standard of care for severe osteoporosis
required co-administration (insufficient calcium/D blunts response and increases fracture risk despite BMD gain). Target 25(OH)D ≥30 ng/mL, calcium 1000-1200…
hypercalcemia from teriparatide can sensitize myocardium → arrhythmia
additive hypercalcemia risk (HCTZ reduces urinary calcium excretion)
(alendronate + teriparatide simultaneously) — the older Black 2003 NEJM data suggested alendronate blunted teriparatide response when given together; this wa…
Quality Indicators
White, fluffy cake (peptides)
Lyophilized peptide should appear as a white, fluffy "cake" filling most of the vial bottom. Indicates proper freeze-drying.
Clear solution after reconstitution
After mixing with bacteriostatic water, the solution should be crystal clear with no particles or cloudiness.
Slight clumping acceptable
Small clumps that fully dissolve with gentle swirling are normal — shipping can cause minor compaction.
Collapsed or melted powder
Powder that looks collapsed, melted, or stuck to vial sides may have been heat-damaged in transit.
Cloudy or particulate solution
Persistent cloudiness or visible particles after gentle mixing indicate degraded or contaminated material.
What to Expect
- Day 1-7Injection / administration protocol established. Tolerability check.
- Week 2-4Early onset of effect — subtle in most users, noticeable in responders.
- Week 4-8Peak benefit window for most peptide cycles.
- Week 8+Cycle decision point: continue, taper, or break.
Side Effects & Safety
Common (>10%): Nausea, arthralgia, mild injection-site reactions, asymptomatic mild hypercalcemia (transient peak 4-6 hr post-dose)
Less common (1-10%): Orthostatic hypotension (first doses), leg cramps, dizziness, headache, hyperuricemia, hypercalciuria
Rare-serious (<1%):
- Symptomatic hypercalcemia — especially with concurrent vitamin D, calcium supplements, thiazide diuretics
- Digoxin sensitization — hypercalcemia potentiates digoxin → arrhythmia risk
- Osteosarcoma (BLACK BOX historically) — Fischer rats given high doses for most of their lifespan developed osteosarcoma at high rates. Human signal: post-marketing surveillance over ~20 years (Forteo Patient Registry, US-only, ~76,000 patients tracked) detected NO excess osteosarcoma above baseline incidence. The 2-year lifetime cap and black box warning were both removed/loosened by FDA in 2020 based on this reassuring human data — the cap was restated as "use longer than 2 years only when continued treatment justified."
- Allergic reactions (rare, including anaphylaxis case reports)
Specific watch periods:
- First 4-6 doses: orthostatic events
- Months 1-3: serum calcium check (immediate baseline + ~1 month + then PRN)
- 24-hour urine calcium baseline if hypercalciuria history
- Annual DXA to verify gain and decision-point for sequencing
Contraindications (label):
- Prior skeletal radiation
- Pre-existing hypercalcemia (any cause)
- Paget's disease of bone
- Unexplained alkaline phosphatase elevation
- Open epiphyses (pediatric — bone still growing) ← This is one reason teriparatide is not used in young adults in the post-epiphyseal-fusion 18-25 window even off-label; the regulatory caution about "active bone growth" lingers.
- Bone metastases or skeletal malignancies, or prior radiation to skeleton
References
Neer et al. 2001 NEJM — Fracture Prevention Trial
pivotal RCT, n=1637, 65% vertebral / 53% non-vertebral fracture reduction
View StudySaag et al. 2007 NEJM — Glucocorticoid-induced osteoporosis
teriparatide superior to alendronate
View StudyKendler et al. 2018 Lancet — VERO trial (vs risedronate)
32137-2) — head-to-head with risedronate, 56% vertebral fracture reduction
View StudyMiller et al. 2016 JAMA — ACTIVE trial (abaloparatide vs teriparatide)
class comparison
View StudyTsai et al. 2013 Lancet — DATA trial (concurrent denosumab+teriparatide)
60856-9) — combination strategy
View StudyFDA 2020 label update removing 2-year cap
duration restriction loosened based on post-marketing data
View StudyBlack et al. 2003 NEJM — alendronate + teriparatide combination
basis for "anabolic before antiresorptive" sequencing rule
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.